Übersetzung für "Esophagitis" in Deutsch

Reflux esophagitis: The treatment time is 4-8 weeks.

Other conditions this medication is used to treat include Zollinger-Ellison syndrome and erosive esophagitis.

The orodispersible effervescent tablets according to the invention are particularly preferably used for the treatment of eosinophilic esophagitis.

Complications to which esophagitis can lead:

Chronic and subacute esophagitis can develop due to the following reasons:

Severe esophagitis may include symptoms of fever and extreme salivation.

This can result in inflammation of the esophagus (esophagitis).

Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age).

It is used to treat a variety of conditions, such as erosive esophagitis and Zollinger-Ellison syndrome.

Radiographic studies, including X-ray or ultrasound imaging, may help in the diagnosis of esophagitis.

However, signs may indicate such serious diseases as esophagitis, gastritis and even stomach cancer.

Herpes simplex esophagitis (Albertinen-Krankenhaus)

There are limited pharmacokinetic data available in the paediatric population (59 subjects with eosinophilic esophagitis, 55 subjects with severe refractory eosinophilic asthma).

In patients with severe esophagitis Losec 40 mg once daily is recommended and healing is usually achieved within eight weeks.

Intravenous mepolizumab pharmacokinetics was evaluated by population pharmacokinetic analysis in a paediatric study conducted in subjects aged 2-17 years old with eosinophilic esophagitis.

The treatment with this medicinal product should be initiated by a physician experienced in the diagnosis and treatment of eosinophilic esophagitis.

There are limited long term safety data from 46 children who received maintenance therapy of omeprazole during a clinical study for severe erosive esophagitis for up to 749 days.

There are limited pharmacokinetic data available in the paediatric population (59 subjects with eosinophilic esophagitis, 19 subjects with severe asthma).

Intravenous mepolizumab pharmacokinetics was evaluated by population pharmacokinetic analysis in a paediatric study conducted in subjects aged 2–17 years old with eosinophilic esophagitis.

These include, inter alia, allergies, inflammations, autoimmune diseases, shock, pain and, more specifically, asthma, cough, bronchitis, rhinitis, chronic obstructive pulmonary disorders, pneumonitis, septic shock, endotoxic shock, anaphylactic shock, disseminated intravascular coagulation, arthritis, rheumatism, osteoarthritis, lumbago, inflammation-induced bone resorption, conjunctivitis, iritis, headache, migraine, toothache, backache, cancer pain, postoperative pain, traumata (wounds, burns, etc.), rash, erythemas, edemas, eczemas, dermatitis, zoster, herpes, pruritus, psoriasis, lichen, inflammatory bowel disorders, hepatitis, pancreatitis, gastritis, esophagitis, food allergies, ulcers, irritable colon, angina, cerebral edema, low blood pressure, thrombosis, craniocerebral and spinal trauma, premature birth, atherosclerosis, ascites associated with malignant cancer, tumor metastases, cerebral edema associated with tumors, heat damage to the brain and viral diseases.

They are likewise suitable, on account of their strong gastric secretion-inhibiting activity, as excellent therapeutics for the therapy and prophylaxis of reflux esophagitis.